HER2 and EGFR: Signalling mechanisms and next generation cancer therapies

Add to your list(s) Download to your calendar using vCal

• Yosef Yarden, Weizmann Institute of Science, Israel
• Thursday 18 July 2013, 13:00-14:00
• Cancer Research UK Cambridge Research Institute, Lecture Theatre.

If you have a question about this talk, please contact Kate Davenport.

Tumor-specific combinations of oncogenic mutations often free cancer cells from their reliance on growth factors. One important example comprises the epidermal growth factor receptor (EGFR) and its kin, HER2 . In tumours, both EGFR and HER2 frequently display overexpression, internal deletions and point mutations. Accordingly, monoclonal antibodies and kinase inhibitors specific to these receptors have been approved for clinical application. My lecture will introduce our efforts to develop novel agents able to intercept growth factor signalling in tumours. Examples include aptamers, antibody combinations and decoy receptors. Alongside, my laboratory is interested in molecular mechanisms underlying the ability of EGFR and HER2 to enhance cell proliferation and promote invasive growth. I will focus on a model that portrays growth factor signalling as a pulsatile mechanism that eliminates noise and commits cells to consistent extracellular ques. In addition, I will describe several transcription-based mechanisms that explain the invasive behavior of HER2 and EGF -driven cancer cells.

This talk is part of the Cancer Research UK Cambridge Institute (CRUK CI) Seminars in Cancer series.

This talk is included in these lists:

• All Talks (aka the CURE list)
• Biology
• CCC talks for website
• CRUK CI Seminars
• Cancer Research UK Cambridge Institute (CRUK CI) Seminars in Cancer
• Cancer Research UK Cambridge Research Institute, Lecture Theatre
• Graduate-Seminars
• Liam
• Life Sciences
• Life Sciences
• ME Seminar
• PMRFPS's
• cri
• my_list
• other talks
• se393's list
• sfm36

Note that ex-directory lists are not shown.